We are in a good position because we still pose a potential threat on multiple fronts. When most small biotech firms explode like we did in June 2020 once they are attacked they can't survive because they only have ONE indication. But LL masks CCR5 with side effects of upset stomach. We only need one hit on one front where there many to choose from.
Some BP will get an upset stomach from us yet.